Status:
COMPLETED
Use of Activated Recombinant FVII in Spinal Surgery
Lead Sponsor:
Novo Nordisk A/S
Conditions:
Acquired Bleeding Disorder
Spinal Fusion
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
This trial is conducted in the United States of America (USA). The purpose of this clinical research trial is to understand how safe and effective Recombinant Activated FVII is for reducing bleeding a...
Eligibility Criteria
Inclusion
- Elective spinal fusion surgery.
Exclusion
- History of thrombotic disorders (myocardial infarction, deep vein thrombosis, pulmonary embolism, stroke, disseminated intravascular coagulation or peripheral artery thrombosis)
- Any trauma within the last 3 months leading to hospitalization \> 24 hours
- Angina or known coronary artery disease
Key Trial Info
Start Date :
July 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2006
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT00102037
Start Date
July 1 2004
End Date
February 1 2006
Last Update
January 13 2017
Active Locations (14)
Enter a location and click search to find clinical trials sorted by distance.
1
Novo Nordisk Investigational Site
Sacramento, California, United States, 95817
2
Novo Nordisk Investigational Site
San Francisco, California, United States, 94143-0728
3
Novo Nordisk Investigational Site
Washington D.C., District of Columbia, United States, 20007
4
Novo Nordisk Investigational Site
Miami, Florida, United States, 33136